OncoCyte has begun preparations to launch liquid biopsy tests this year. This announcement comes after a 300-person study has confirmed the validity of the liquid biopsy. The biopsy’s correct detection rate for lung cancer was 90% and 62% for benign nodules. The innovative diagnostic will prevent invasive biopsy procedures from being necessary, and will also be the first liquid biopsy for the use of confirming a cancer diagnosis. This was the second study executed to confirm the abilities of the biopsy, as Wistar had previously tested the biopsy. Commercial rights were handed over to OncoCyte from Wistar in January. Read the full article here.
